Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 4pertuzumab 2pembrolizumab 2durvalumab 2Paclitaxel 2Docetaxel 2Capecitabine 2ulocuplumab 1tremelimumab 1tazarotene 1talazoparib 1romiplostim 1pexidartinib 1pamiparib 1onartuzumab 1magrolimab 1entrectinib 1cobimetinib 1atezolizumab 1Sunitinib 1Rifampin 1Ramucirumab 1Radiosurgery 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Midazolam 1MK-4166 1LY3022855 1LY2510924 1LY-2157299 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumor × onartuzumab × Clear all
NCT02488330 2019-07-23

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Hoffmann-La Roche

Phase 3 Completed
12 enrolled 8 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡